Kuvan
Total Payments
$4.7M
Transactions
2,188
Doctors
204
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $316.21 | 10 | 9 |
| 2023 | $265.04 | 11 | 7 |
| 2022 | $126,515 | 64 | 22 |
| 2021 | $575,782 | 152 | 25 |
| 2020 | $555,247 | 136 | 15 |
| 2019 | $882,277 | 376 | 60 |
| 2018 | $1.4M | 821 | 108 |
| 2017 | $1.2M | 618 | 91 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $3.8M | 913 | 82.5% |
| Education | $465,464 | 491 | 10.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $145,814 | 83 | 3.1% |
| Travel and Lodging | $119,069 | 183 | 2.6% |
| Food and Beverage | $32,802 | 505 | 0.7% |
| Grant | $22,398 | 3 | 0.5% |
| Consulting Fee | $18,535 | 9 | 0.4% |
| Charitable Contribution | $12,000 | 1 | 0.3% |
Payments by Type
Research
$3.8M
913 transactions
General
$816,083
1,275 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| PKU Demographics, Outcomes, and Safety Registry | BioMarin Pharmaceutical Inc. | $3.2M | 0 |
| Effect of Kuvan on Neurocognitive Function, Blood Phenylalanine Level, Safety, and Pharmacokinetics in Children With PKU | BioMarin Pharmaceutical Inc. | $294,340 | 0 |
| Determining Kuvan Responsiveness in Amish PKU Patients Homozygous for the c.1066-11GA Mutation | BioMarin Pharmaceutical Inc. | $121,600 | 0 |
| The Brain, Neurological Features and Neuropsychological Functioning in Adults with Sapropterin Dihydrochloride treated Phenylketonuria | BioMarin Pharmaceutical Inc. | $53,051 | 0 |
| The Brain, Neurological Features and Neuropsychological Functioning in Adults with Sapropterin Dihydrochloride treated PKU | BioMarin Pharmaceutical Inc. | $43,011 | 0 |
| An Observational Study to Collect the Effectiveness and Safety Data of KUVAN Retrospectively in Chinese Subjects with Hyperphenylalaninemia HPA (Caused by Tetrahydrobiopterin BH4) Deficiency | BioMarin Pharmaceutical Inc. | $25,487 | 0 |
| Determining Kuvan Responsiveness in Amish PKU Patients Homozygous for the c.1066-11G>A Mutation | BioMarin Pharmaceutical Inc. | $25,400 | 0 |
| An Observational Study to Collect the Effectiveness and Safety Data ofKUVAN Retrospectively in Chinese Subjects withHyperphenylalaninemia HPA) Caused by Tetrahydrobiopterin BH4)Deficiency | BioMarin Pharmaceutical Inc. | $11,133 | 0 |
| An Observational Study to Collect the Effectiveness and Safety Data ofKUVAN Retrospectively in Chinese Subjects withHyperphenylalaninemia (HPA) Caused by Tetrahydrobiopterin (BH4)Deficiency | BioMarin Pharmaceutical Inc. | $11,084 | 0 |
| An Observational Study to Collect the Effectiveness and Safety Data ofKUVAN Retrospectively in Chinese Subjects with Hyperphenylalaninemia HPA (Caused by Tetrahydrobiopterin BH4) Deficiency | BioMarin Pharmaceutical Inc. | $6,968 | 0 |
| MPS VI Clinical Surveillance Program CSP) | BioMarin Pharmaceutical Inc. | $6,400 | 0 |
| Morquio A Registry Study MARS) | BioMarin Pharmaceutical Inc. | $300.00 | 1 |
| Phenylketonuria (PKU) Demographic, Outcomes, and Safety Registry (PKUDOS) | BioMarin Pharmaceutical Inc. | $252.00 | 0 |
| An Open-label Extension Study to Evaluate the Safety and Efficacy of Subcutaneous Injections of Pegvaliase 40 mgday Dose) in Adults with Phenylketonuria | BioMarin Pharmaceutical Inc. | $33.33 | 0 |
Top Doctors Receiving Payments for Kuvan
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Galveston, TX | $4.0M | 923 |
| , MD | Clinical Genetics (M.D.) | Gainesville, FL | $90,489 | 103 |
| , MD | Clinical Genetics (M.D.) | Chicago, IL | $81,700 | 123 |
| , MD | Clinical Biochemical Genetics | Salt Lake City, UT | $58,294 | 73 |
| , MD | Clinical Genetics (M.D.) | Aurora, CO | $41,577 | 53 |
| , M.D | Pediatrics | Houston, TX | $32,891 | 43 |
| , MD | Clinical Biochemical Genetics | Portland, OR | $32,864 | 49 |
| , MD, PHD | Medical Genetics, Ph.D. Medical Genetics | Pittsburgh, PA | $31,120 | 43 |
| , M.D | Neurodevelopmental Disabilities | Haddonfield, NJ | $29,845 | 51 |
| , MD | Orthopaedic Surgery | Seattle, WA | $29,217 | 5 |
| , MD | Clinical Biochemical Genetics | Boston, MA | $28,832 | 44 |
| , MD | Clinical Genetics (M.D.) | Phoenix, AZ | $19,411 | 34 |
| , M.D | Clinical Genetics (M.D.) | Philadelphia, PA | $18,010 | 38 |
| , M.D | Neurodevelopmental Disabilities | Salt Lake City, UT | $17,980 | 24 |
| , M.D | Clinical Genetics (M.D.) | Milwaukee, WI | $17,336 | 31 |
| , M.D | Clinical Genetics (M.D.) | Tampa, FL | $17,100 | 10 |
| , M.D | Clinical Genetics (M.D.) | Lexington, KY | $16,878 | 24 |
| , MD | Clinical Genetics (M.D.) | Orlando, FL | $14,554 | 33 |
| , M.D | Clinical Biochemical Genetics | Boston, MA | $11,684 | 12 |
| , MD | Pediatrics | Pittsburgh, PA | $11,096 | 9 |
| , M.D | Clinical Genetics (M.D.) | Morristown, NJ | $9,465 | 16 |
| , M.D | Clinical Genetics (M.D.) | Los Angeles, CA | $8,528 | 8 |
| , MD | Clinical Genetics (M.D.) | Cleveland, OH | $6,291 | 7 |
| , MD | Specialist | Carlsbad, CA | $5,931 | 5 |
| , MD | Family Medicine | Salt Lake City, UT | $5,871 | 7 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $4.7M
- Total Doctors 204
- Transactions 2,188
About Kuvan
Kuvan is a drug associated with $4.7M in payments to 204 healthcare providers, recorded across 2,188 transactions in the CMS Open Payments database. The primary manufacturer is BioMarin Pharmaceutical Inc..
Payment data is available from 2017 to 2024. In 2024, $316.21 was paid across 10 transactions to 9 doctors.
The most common payment nature for Kuvan is "Unspecified" ($3.8M, 82.5% of total).
Kuvan is associated with 14 research studies, including "PKU Demographics, Outcomes, and Safety Registry" ($3.2M).